An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Status:
Recruiting
Trial end date:
2026-03-15
Target enrollment:
Participant gender:
Summary
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of
aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and
tolerability data, including assessments of cardiac function and steady-state
Pharmacokinetics (PK) during chronic dosing with aficamten.